2.1
Daridorexant (QUVIVIQ, Idorsia) is indicated for 'the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning'.
2 Information about daridorexant
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for daridorexant.
Price
2.3
The list price for the 50‑mg or the 25‑mg dose is £1.40 per day (£42 per pack of 30 tablets; company submission).